Review



rabbit monoclonal anti py stat1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc rabbit monoclonal anti py stat1
    Primers sequence used in SYBR-based reverse transcription-quantitative PCR.
    Rabbit Monoclonal Anti Py Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1536 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti py stat1/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1536 article reviews
    rabbit monoclonal anti py stat1 - by Bioz Stars, 2026-02
    98/100 stars

    Images

    1) Product Images from "Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer"

    Article Title: Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer

    Journal: Oncology Letters

    doi: 10.3892/ol.2024.14571

    Primers sequence used in SYBR-based reverse transcription-quantitative PCR.
    Figure Legend Snippet: Primers sequence used in SYBR-based reverse transcription-quantitative PCR.

    Techniques Used: Sequencing

    Increased IRF9 expression in sorafenib-resistant liver cancer cells. (A) Procedure for establishing sorafenib-resistant liver cancer cells. (B) liver cancer cells were treated with an increasing dose of sorafenib for 24 h. Cell viability was measured by MTT assay. (C) Protein levels of STAT1, STAT2 and IRF9 from immunoblotting. (D) mRNA levels of STAT1, STAT2 and IRF9 from reverse transcription-quantitative PCR. *P<0.05 and **P<0.01 vs. liver cancer cell lines (Huh-7 and HepG2). IRF9, interferon regulatory factor 9; wks, weeks; p-, phosphorylated.
    Figure Legend Snippet: Increased IRF9 expression in sorafenib-resistant liver cancer cells. (A) Procedure for establishing sorafenib-resistant liver cancer cells. (B) liver cancer cells were treated with an increasing dose of sorafenib for 24 h. Cell viability was measured by MTT assay. (C) Protein levels of STAT1, STAT2 and IRF9 from immunoblotting. (D) mRNA levels of STAT1, STAT2 and IRF9 from reverse transcription-quantitative PCR. *P<0.05 and **P<0.01 vs. liver cancer cell lines (Huh-7 and HepG2). IRF9, interferon regulatory factor 9; wks, weeks; p-, phosphorylated.

    Techniques Used: Expressing, MTT Assay, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction

    U-ISGs unresponsiveness depends on STAT1, STAT2 and IRF9 in Huh-7-SR cells. (A) Huh-7-SR cells were transfected with si-control, si-STAT1, si-STAT2, and si-IRF9. Then, 48 h after transfection, cells were harvested and immunoblotting of STAT1, STAT2 and IRF9 was performed. (B) mRNA levels of U-ISGs were measured by reverse transcription-quantitative PCR. (C) After transfection, Huh-7-SR cells were treated with an increasing dose of sorafenib for 24 h. **P<0.01 vs. siControl. IRF, interferon regulatory factor; si, small interfering; OAS1; oligoadenylate synthetase 1; IFI27, Interferon Alpha Inducible Protein 27.
    Figure Legend Snippet: U-ISGs unresponsiveness depends on STAT1, STAT2 and IRF9 in Huh-7-SR cells. (A) Huh-7-SR cells were transfected with si-control, si-STAT1, si-STAT2, and si-IRF9. Then, 48 h after transfection, cells were harvested and immunoblotting of STAT1, STAT2 and IRF9 was performed. (B) mRNA levels of U-ISGs were measured by reverse transcription-quantitative PCR. (C) After transfection, Huh-7-SR cells were treated with an increasing dose of sorafenib for 24 h. **P<0.01 vs. siControl. IRF, interferon regulatory factor; si, small interfering; OAS1; oligoadenylate synthetase 1; IFI27, Interferon Alpha Inducible Protein 27.

    Techniques Used: Transfection, Control, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction

    Mechanisms of U-ISGF3 complex in sorafenib resistance. U-ISGF complex, unphosphorylated interferon-stimulated gene factor-3; U-STAT1, unphosphorylated signal transducer and activator of transcription 1; U-STAT2, unphosphorylated signal transducer and activator of transcription 2; IRF9, interferon regulatory factor 9; U-ISGs, Unphosphorylated interferon-stimulated genes.
    Figure Legend Snippet: Mechanisms of U-ISGF3 complex in sorafenib resistance. U-ISGF complex, unphosphorylated interferon-stimulated gene factor-3; U-STAT1, unphosphorylated signal transducer and activator of transcription 1; U-STAT2, unphosphorylated signal transducer and activator of transcription 2; IRF9, interferon regulatory factor 9; U-ISGs, Unphosphorylated interferon-stimulated genes.

    Techniques Used:



    Similar Products

    rabbit monoclonal anti py stat1  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc rabbit monoclonal anti py stat1
    Primers sequence used in SYBR-based reverse transcription-quantitative PCR.
    Rabbit Monoclonal Anti Py Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti py stat1/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    rabbit monoclonal anti py stat1 - by Bioz Stars, 2026-02
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Primers sequence used in SYBR-based reverse transcription-quantitative PCR.

    Journal: Oncology Letters

    Article Title: Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer

    doi: 10.3892/ol.2024.14571

    Figure Lengend Snippet: Primers sequence used in SYBR-based reverse transcription-quantitative PCR.

    Article Snippet: After blocking the membrane in TBS containing 5% skim milk for 1 h. The antibodies used for immunoblotting were as follows: rabbit monoclonal anti-STAT1 (Cell signaling Technology, Cat#9176S), rabbit monoclonal anti-PY STAT1 (Cell signaling Technology, Cat#9167S), rabbit polyclonal anti-STAT2 (Cell signaling Technology, Cat#4594S), rabbit polyclonal anti-PY STAT2 (Cell signaling Technology, Cat#4441S), rabbit monoclonal IRF9 (Cell signaling Technology, Cat#28492), and horseradish peroxidase-conjugated secondary antibody (1:5,000).

    Techniques: Sequencing

    Increased IRF9 expression in sorafenib-resistant liver cancer cells. (A) Procedure for establishing sorafenib-resistant liver cancer cells. (B) liver cancer cells were treated with an increasing dose of sorafenib for 24 h. Cell viability was measured by MTT assay. (C) Protein levels of STAT1, STAT2 and IRF9 from immunoblotting. (D) mRNA levels of STAT1, STAT2 and IRF9 from reverse transcription-quantitative PCR. *P<0.05 and **P<0.01 vs. liver cancer cell lines (Huh-7 and HepG2). IRF9, interferon regulatory factor 9; wks, weeks; p-, phosphorylated.

    Journal: Oncology Letters

    Article Title: Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer

    doi: 10.3892/ol.2024.14571

    Figure Lengend Snippet: Increased IRF9 expression in sorafenib-resistant liver cancer cells. (A) Procedure for establishing sorafenib-resistant liver cancer cells. (B) liver cancer cells were treated with an increasing dose of sorafenib for 24 h. Cell viability was measured by MTT assay. (C) Protein levels of STAT1, STAT2 and IRF9 from immunoblotting. (D) mRNA levels of STAT1, STAT2 and IRF9 from reverse transcription-quantitative PCR. *P<0.05 and **P<0.01 vs. liver cancer cell lines (Huh-7 and HepG2). IRF9, interferon regulatory factor 9; wks, weeks; p-, phosphorylated.

    Article Snippet: After blocking the membrane in TBS containing 5% skim milk for 1 h. The antibodies used for immunoblotting were as follows: rabbit monoclonal anti-STAT1 (Cell signaling Technology, Cat#9176S), rabbit monoclonal anti-PY STAT1 (Cell signaling Technology, Cat#9167S), rabbit polyclonal anti-STAT2 (Cell signaling Technology, Cat#4594S), rabbit polyclonal anti-PY STAT2 (Cell signaling Technology, Cat#4441S), rabbit monoclonal IRF9 (Cell signaling Technology, Cat#28492), and horseradish peroxidase-conjugated secondary antibody (1:5,000).

    Techniques: Expressing, MTT Assay, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction

    U-ISGs unresponsiveness depends on STAT1, STAT2 and IRF9 in Huh-7-SR cells. (A) Huh-7-SR cells were transfected with si-control, si-STAT1, si-STAT2, and si-IRF9. Then, 48 h after transfection, cells were harvested and immunoblotting of STAT1, STAT2 and IRF9 was performed. (B) mRNA levels of U-ISGs were measured by reverse transcription-quantitative PCR. (C) After transfection, Huh-7-SR cells were treated with an increasing dose of sorafenib for 24 h. **P<0.01 vs. siControl. IRF, interferon regulatory factor; si, small interfering; OAS1; oligoadenylate synthetase 1; IFI27, Interferon Alpha Inducible Protein 27.

    Journal: Oncology Letters

    Article Title: Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer

    doi: 10.3892/ol.2024.14571

    Figure Lengend Snippet: U-ISGs unresponsiveness depends on STAT1, STAT2 and IRF9 in Huh-7-SR cells. (A) Huh-7-SR cells were transfected with si-control, si-STAT1, si-STAT2, and si-IRF9. Then, 48 h after transfection, cells were harvested and immunoblotting of STAT1, STAT2 and IRF9 was performed. (B) mRNA levels of U-ISGs were measured by reverse transcription-quantitative PCR. (C) After transfection, Huh-7-SR cells were treated with an increasing dose of sorafenib for 24 h. **P<0.01 vs. siControl. IRF, interferon regulatory factor; si, small interfering; OAS1; oligoadenylate synthetase 1; IFI27, Interferon Alpha Inducible Protein 27.

    Article Snippet: After blocking the membrane in TBS containing 5% skim milk for 1 h. The antibodies used for immunoblotting were as follows: rabbit monoclonal anti-STAT1 (Cell signaling Technology, Cat#9176S), rabbit monoclonal anti-PY STAT1 (Cell signaling Technology, Cat#9167S), rabbit polyclonal anti-STAT2 (Cell signaling Technology, Cat#4594S), rabbit polyclonal anti-PY STAT2 (Cell signaling Technology, Cat#4441S), rabbit monoclonal IRF9 (Cell signaling Technology, Cat#28492), and horseradish peroxidase-conjugated secondary antibody (1:5,000).

    Techniques: Transfection, Control, Western Blot, Reverse Transcription, Real-time Polymerase Chain Reaction

    Mechanisms of U-ISGF3 complex in sorafenib resistance. U-ISGF complex, unphosphorylated interferon-stimulated gene factor-3; U-STAT1, unphosphorylated signal transducer and activator of transcription 1; U-STAT2, unphosphorylated signal transducer and activator of transcription 2; IRF9, interferon regulatory factor 9; U-ISGs, Unphosphorylated interferon-stimulated genes.

    Journal: Oncology Letters

    Article Title: Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer

    doi: 10.3892/ol.2024.14571

    Figure Lengend Snippet: Mechanisms of U-ISGF3 complex in sorafenib resistance. U-ISGF complex, unphosphorylated interferon-stimulated gene factor-3; U-STAT1, unphosphorylated signal transducer and activator of transcription 1; U-STAT2, unphosphorylated signal transducer and activator of transcription 2; IRF9, interferon regulatory factor 9; U-ISGs, Unphosphorylated interferon-stimulated genes.

    Article Snippet: After blocking the membrane in TBS containing 5% skim milk for 1 h. The antibodies used for immunoblotting were as follows: rabbit monoclonal anti-STAT1 (Cell signaling Technology, Cat#9176S), rabbit monoclonal anti-PY STAT1 (Cell signaling Technology, Cat#9167S), rabbit polyclonal anti-STAT2 (Cell signaling Technology, Cat#4594S), rabbit polyclonal anti-PY STAT2 (Cell signaling Technology, Cat#4441S), rabbit monoclonal IRF9 (Cell signaling Technology, Cat#28492), and horseradish peroxidase-conjugated secondary antibody (1:5,000).

    Techniques: